Namita Goyal

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (5)

• Quantitative Measures of Time to Loss of 15% Vital Capacity and Survival Extension in Slowly Progressive Amyotrophic Lateral Sclerosis (ALS) Patients Treated with the Immune Regulator NP001 Suggests an Immunopathogenic Subset of ALS
  Biomedicines 2025 DOI: 10.3390/biomedicines13123060
  +Save
• The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms
  The Journal of Rheumatology 2024 DOI: 10.3899/jrheum.2023-1137
  +Save
• The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis
  Biomedicines 2024 DOI: 10.3390/biomedicines12102367
  +Save
• Correlations of disease severity outcome measures in inclusion body myositis
  Neuromuscular Disorders 2022 DOI: 10.1016/j.nmd.2022.08.005
  +Save
• MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis in a Phase IIb/III Study: COMBAT-ALS Study Design
  Neurodegenerative Disease Management 2021 DOI: 10.2217/nmt-2021-0042
  +Save